Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Claude Bystryn

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Archives of Dermatology|October 11, 2002
Can nondermatologists really recognize potentially dangerous skin lesions as well as dermatologists?Jean-Claude Bystryn
Archives of Dermatology|June 20, 2007
Increasing ratio of thin to thick melanoma lesions: pathogenesis and early detection of this cancerJean-Claude Bystryn
Archives of Dermatology|June 20, 2007
A confusing message will not improve the detection of melanomaJean-Claude Bystryn
Archives of Dermatology|July 23, 2008
Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoidJean-Claude Bystryn
Dermatologic Clinics|October 17, 2002
Vaccines for melanomaJean-Claude Bystryn
Expert Opinion on Emerging Drugs|July 2, 2005
Emerging melanoma vaccinesJean-Claude Bystryn
Archives of Dermatology|May 21, 2008
Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodiesAnnette Czernik, Jean-Claude Bystryn
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic miceDean Johnston, Jean-Claude Bystryn
Vaccine|November 29, 2005
Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccineDean Johnston, Jean-Claude Bystryn
Journal of the American Academy of Dermatology|August 21, 2007
Does imiquimod work in infantile hemangiomas?Annette Czernik, Jean-Claude Bystryn
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Archives of Dermatology|October 11, 2002
Can nondermatologists really recognize potentially dangerous skin lesions as well as dermatologists?Jean-Claude Bystryn
Archives of Dermatology|June 20, 2007
Increasing ratio of thin to thick melanoma lesions: pathogenesis and early detection of this cancerJean-Claude Bystryn
Archives of Dermatology|June 20, 2007
A confusing message will not improve the detection of melanomaJean-Claude Bystryn
Archives of Dermatology|July 23, 2008
Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoidJean-Claude Bystryn
Dermatologic Clinics|October 17, 2002
Vaccines for melanomaJean-Claude Bystryn
Expert Opinion on Emerging Drugs|July 2, 2005
Emerging melanoma vaccinesJean-Claude Bystryn
Archives of Dermatology|May 21, 2008
Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodiesAnnette Czernik, Jean-Claude Bystryn
Cancer Immunology, Immunotherapy : CII|February 5, 2005
Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic miceDean Johnston, Jean-Claude Bystryn
Vaccine|November 29, 2005
Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccineDean Johnston, Jean-Claude Bystryn
Journal of the American Academy of Dermatology|August 21, 2007
Does imiquimod work in infantile hemangiomas?Annette Czernik, Jean-Claude Bystryn
Pageof 5